WEP Warwick Evans Publishing

International Journal of Public Health and Medical Research

ISSN: 3006-3752 (Online) | Volume 1, Number 1, Year 2024
DOI: https://doi.org/10.62051/ijphmr.v1n1.01
Journal homepage: https://wepub.org/index.php/IJPHMR/index

Exploring intervention strategies for cellular senescence under microgravity

Daoyue Lai

Okayama University, 1 Chome-1-1 Tsushimanaka, Kita Ward, Okayama, 700-8530, Japan

ABSTRACT

This paper explores intervention strategies for mitigating cellular senescence under microgravity, a significant challenge for space exploration and astronaut health. It delves into the mechanisms of accelerated cellular aging in microgravity, including oxidative stress and DNA damage, and proposes interventions ranging from pharmacological inhibitors to lifestyle modifications. The research underscores the potential of understanding aging in space to innovate strategies against aging and age-related diseases on Earth, thereby bridging space science and medical science for mutual advancements. Through a comprehensive review of current knowledge, potential mechanisms, impacts, and intervention strategies, this study aims to enhance astronaut health during prolonged missions and contribute to gerontology.

KEYWORDS

Cellular Senescence; Microgravity; Space Exploration.

1. INTRODUCTION

The relentless pursuit of understanding human physiology in the unique environment of space has uncovered several pivotal challenges, one of which is cellular senescence under microgravity conditions. Cellular senescence, a state of permanent cell cycle arrest, emerges as a double-edged sword within the biological realm. While it plays a crucial role in tumor suppression and wound healing, its accumulation is associated with aging and various age-related diseases. The microgravity environment of space exacerbates cellular senescence, presenting a significant hurdle for long-term space exploration and the health of astronauts.

This phenomenon under microgravity poses a unique challenge, as it diverges from the senescence pathways observed under Earth's gravitational forces. Microgravity disrupts cellular architecture, signaling pathways, and the extracellular matrix, leading to accelerated cellular aging, enhanced senescent cell accumulation, and altered tissue homeostasis. The implications of these changes are profound, affecting astronaut health during and after space missions, with potential long-term consequences such as increased susceptibility to cardiovascular diseases, muscle degeneration, and impaired tissue repair and regeneration.

Given the critical implications of cellular senescence under microgravity for space exploration and human health, this paper aims to explore intervention strategies that can mitigate these adverse effects. We delve into the underlying mechanisms of accelerated cellular senescence in microgravity, examining the role of oxidative stress, DNA damage response, changes in gene expression, and the impact on the surrounding extracellular matrix. By understanding these pathways, we can identify potential targets for intervention, ranging from pharmacological inhibitors and antioxidants to gene therapy and lifestyle modifications.

Our exploration is not only crucial for enhancing astronaut health during prolonged space missions but also offers the potential to understand aging processes in a novel environment, contributing to the broader field of gerontology. The insights gained from studying cellular senescence under microgravity conditions could lead to innovative strategies to combat aging and age-related diseases on Earth, making this research invaluable to both space science and medical science.

In the following sections, we will review the current state of knowledge regarding cellular senescence under microgravity, discuss potential mechanisms and impacts, and propose intervention strategies to counteract these effects. This comprehensive approach aims to pave the way for more effective management of cellular senescence in space, contributing to the success of future long-duration space missions and enhancing our understanding of the aging process.

2. POTENTIAL MECHANISMS AND IMPACTS

The unique environment of microgravity significantly influences cellular aging processes, accelerating cellular senescence through various mechanisms and leading to profound impacts on astronaut health. This acceleration is attributed to a constellation of cellular and molecular alterations induced by the space environment.

2.1. Mechanisms Facilitating Cellular Senescence in Microgravity

Microgravity disrupts cellular structure and function, leading to altered signaling pathways and inducing stress responses that promote senescence (Smith et al., 2018). The lack of gravitational force affects cytoskeletal organization and cell morphology, crucial for maintaining normal cell function and signaling (Jones & Barr, 2017). Additionally, the space environment's increased radiation levels exacerbate oxidative stress, damaging DNA, proteins, and lipids, thereby accelerating the senescence process (Lee & Lee, 2019). The DNA damage response (DDR) becomes overly active in microgravity, perpetuating cellular arrest and entry into senescence (Davis & Kipling, 2018). Furthermore, telomere attrition, a hallmark of cellular aging, is significantly accelerated in space, diminishing the cellular replication potential and hastening senescence onset (Tanaka et al., 2020). Changes in gene expression under microgravity conditions also contribute to senescence, with upregulation of genes associated with cell cycle arrest, apoptosis, and the senescence-associated secretory phenotype (SASP) (Martin & McGinnis, 2019).

2.2. Impacts on Human Physiology and Space Missions

In addressing the impact of accelerated cellular senescence on astronaut health within the unique conditions of microgravity, it becomes evident that the repercussions are extensive and multifaceted. Accelerated aging in such an environment significantly heightens the risk of developing age-related diseases, prominently cardiovascular diseases and osteoporosis. The former is exacerbated by endothelial dysfunction and an uptick in oxidative stress, promoting atherosclerosis, while the latter results from an imbalance in bone metabolism—specifically, suppressed bone formation and enhanced resorption—leading to decreased bone density and fragility. Muscle atrophy represents another critical concern, as microgravity induces a catabolic state in muscle tissues, characterized by increased protein breakdown and decreased synthesis, thereby impairing astronauts' physical capabilities and complicating post-mission recovery. Compromised immune function further complicates the health scenario in space. The altered gravitational environment disrupts immune cell activity and hormonal balances, rendering astronauts more susceptible to infections, a vulnerability that is intensified by the stress of space missions. Additionally, senescent cells in microgravity secrete an array of pro-inflammatory cytokines, chemokines, and growth factors, collectively known as the senescence-associated secretory phenotype (SASP). This enhanced secretion contributes to a pro-inflammatory state, adversely affecting wound healing, tissue regeneration, and potentially leading

to chronic inflammation, which poses significant challenges not only during missions but also in post-mission recovery efforts. The amalgamation of these factors underscores the critical need for comprehensive health monitoring and effective countermeasures to mitigate the adverse effects of accelerated cellular senescence in microgravity, ensuring astronauts' well-being during and after long-duration space missions.



Figure 1. Overview of Senescence

3. INTERVENTION STRATEGIES TO COUNTERACT EFFECTS

3.1. Targeting and Eliminating Senescent Cells

Senolytic agents have garnered significant attention for their potential in treating musculoskeletal diseases by selectively inducing apoptosis in senescent cells. These cells, when accumulated beyond a certain threshold, contribute to a variety of age-related diseases and disorders through a pro-inflammatory state known as "inflammaging." This condition leads to tissue dysfunction, impaired regenerative capacity, and further senescent cell accumulation, creating a vicious cycle of damage and disease progression.

P53, BCL-X_L, and BCL-2, as well as receptor tyrosine kinases (RTKs), are some of the major molecules and signaling pathways that are increased in senescent cells. Senolytic techniques target these molecules and pathways in order to cause death in senescent cells in a selective manner. This method not only seeks to eliminate these harmful cells, but it also seeks to ease the inflammation and tissue degeneration that are linked with them, which will ultimately lead to an improvement in tissue function and regeneration, as demonstrated for example in Figure 2.



Figure 2. First- and second-generation senolytic strategies

Clinical trials are currently exploring the efficacy of senolytic compounds like UBX0101 and fisetin in treating osteoarthritis and potentially other musculoskeletal conditions. UBX0101, for instance, targets p53 ubiquitination and has shown promise in eliminating senescent cells, reducing articular cartilage degradation and proteoglycan loss in osteoarthritis through local intra-articular injections. Studies involving both local and systemic delivery of senolytics like UBX0101 and navitoclax have indicated improved outcomes in tissue structure and potential repair, particularly when used in combination in aged models. Fisetin, on the other hand, a flavonoid known for activating sirtuins such as SIRT1, has been suggested to increase longevity and mitigate IL-1β–propagated inflammation in osteoarthritis, with its clinical efficacy currently under assessment.

3.2. Modulating the Senescent Phenotype

Senomorphic agents offer a different therapeutic approach from senolytics by aiming to suppress the harmful effects of senescent cells rather than eliminating them. These agents target the senescence-associated secretory phenotype (SASP), which is a crucial factor in creating a pro-inflammatory environment that contributes to tissue damage and dysfunction. By modulating the SASP or interfering with the signaling pathways that mediate its effects, senomorphics can mitigate the detrimental impact of senescent cells on tissue health, which is especially valuable for chronic treatments where a balance is needed between removing harmful senescent cells and preserving their beneficial roles in wound healing and tissue regeneration.

The research in this area is advanced by utilizing various techniques for identifying and characterizing senescent cells, including markers like p16 and p21, morphological features observable under brightfield microscopy, and the accumulation of lipofuscins and increased lysosomal and mitochondrial abundance. These characteristics not only help in detecting senescent cells but also in assessing the efficacy of senomorphic agents in vivo, by observing changes in these markers and the cellular environment. For example, drugs like rapamycin have been shown to reduce the burden of senescent cells indirectly by improving immune cell function, which may also contribute to the clearance of senescent cells by inhibiting the SASP.

System for testing	Class of drug		New methodologies
	Senolytic	Senomorphic	
p16-reporter mice and/or measuring senescence in multiple tissues using multiple end points (expression of p16, p21 and SASP, and/or decreased SA-ß-gal activity)	Short-term administration of a senolytic must yield a sustained reduction in senescence signal[a]	Chronic treatment with a senomorphic is required for a sustained suppression in senescence signal	• Additional transgenic reporters for markers of senescence such as p21 • Dual reporters for apoptosis and senescence • Analysis of activity in immune-deficient mice
Compare pharmacological ablation of senescent cells to genetic ablation (p16-INK-ATTAC or p16-3MR mice)[b]	A short-term or intermittent course of a senolytic yields the same outcome as using a drug to activate a transgene to ablate senescent cells	Chronic treatment with a senomorphic is required to get the same outcome as genetic ablation of senescent cells	• Additional genetic ablation models such as p21-ATTAC • Analysis of activity in immune-deficient mice
Human tissue explants harbouring senescent cells	Drug treatment yields a reduction in senescence markers (expression of p16, p21 and SASP, and/or decreased SA-ß-gal activity) and an increase in apoptosis markers	Drug treatment yields a suppression in senescence markers (expression of p16, p21 and SASP, and/or decreased SA-ß-gal activity) with no evidence of cell death	CyTOF, in situ hybridization and related approaches to colocalize downregulation of senescence with upregulation of apoptosis markers as well as cell identity markers
Transplantation of labelled senescent cells into a host organism; the method of labelling should be independent of senescence (e.g. a ubiquitous rather than a p16 promoter)	Short-term or intermittent administration of a senolytic must yield a long-term attenuation of labelled cells, as well as expression of senescence end points	Chronic administration of a senomorphic will suppress senescence end points but not attenuate the signal from the labelled cells	• Transplantation of cells dually labelled with markers expressed from senescence-dependent and senescence-independent promoters • Monitor both markers to distinguish between senolytics and senomorphics
Measure therapeutic efficacy in aged or diseased organisms	Short-term or intermittent intervention with a senolytic must yield a sustained health benefit in old or diseased organisms	Chronic administration of a senomorphic is required to yield a sustained health benefit in old or diseased organisms	Coordinate analysis of therapeutic efficacy and a reduction of senescence using bioluminescent reporters or serum markers with short or intermittent treatment in models of natural and accelerated ageing

Figure 3. Approaches for demonstrating the mechanism of action of senotherapeutics

This indicates the complexity and potential of senomorphic therapy in addressing the challenges of aging and related diseases. By targeting the SASP, senomorphics provide a promising strategy to improve tissue health and function, potentially leading to therapies that can manage the balance between clearing harmful senescent cells and maintaining the necessary senescent cells for tissue repair and regeneration. The ongoing research and development of senomorphic agents are crucial for understanding their mechanism of action, specificity, selectivity, and overall impact on health and disease management.

4. CHALLENGES AND FUTURE DIRECTIONS

In order to reach their full potential in clinical applications, the development of senotherapies, which include both senolytic and senomorphic drugs, is currently at a critical juncture. There are various hurdles that need to be solved in order to realize their full potential. The development and validation of particular markers for senescent cells is a key challenge that has to be addressed. Given the heterogeneity of senescent cells across a variety of tissues and situations, it is difficult to discover universal markers that are capable of distinguishing senescent cells in a reliable manner. It is essential to have this level of specificity in order to prevent off-target effects, which could potentially disrupt normal tissue function or lead to undesired outcomes.

One such obstacle is gaining better grasp of the various functions that senescence plays in both health and disease. Senescence has a dual purpose, as it can be advantageous, such as in the process of wound healing and tissue regeneration, but it can also be detrimental, as it does contribute to the aging process and chronic diseases. This dual nature provides a challenge for the development of medicines that are capable of selectively inhibiting the negative effects of senescent cells while simultaneously conserving the positive functions of these cells.

Furthermore, there is still a concern regarding the potential adverse consequences of senotherapeutic procedures as well as their safety over the long term. Given that these treatments could be utilized to treat chronic illnesses that are related with aging, it is necessary to have a thorough grasp of their

long-term influence in order to guarantee that they do not interfere with the normal biological processes or result in unfavorable outcomes over the course of time.

The development of senotherapeutic techniques is going to be the primary focus of future research paths, which are going to be successful in addressing these issues. The creation of therapies with enhanced specificity and safety profiles, the discovery of new, more specific targets for both senolytic and senomorphic medicines, and the performance of large-scale clinical trials to evaluate the efficacy and safety of the agents over the long term in humans are all included in this. For such efforts to be successful, a multidisciplinary strategy will be required, which will involve combining insights from cellular and molecular biology, pharmacology, and clinical medicine. This will allow these promising medicines to be efficiently translated from the bench to the bedside.

The field of senotherapy is continuously undergoing development, and these challenges present prospects for substantial advances that have the potential to revolutionize the treatment of age-related diseases and ailments, ultimately leading to an improvement in the quality of life for populations who are becoming older all over the world.

5. CONCLUSION AND DISCUSSION

The exploration of senotherapeutic strategies, specifically through senolytic and senomorphic agents, offers a promising avenue for addressing the challenges associated with cellular senescence and its contribution to age-related diseases and musculoskeletal disorders. Senolytics, aiming to selectively eliminate senescent cells, and senomorphics, designed to suppress the harmful effects of the SASP, have both shown potential in preclinical and early clinical studies for mitigating the impact of senescent cells on tissue health and function.

The development and clinical application of these therapies, on the other hand, face several challenges. These challenges include the identification of specific markers for senescent cells in order to reduce off-target effects, the comprehension of the complex roles that senescence plays in a variety of tissues and contexts, and the management of potential side effects that may be caused by long-term treatment. These problems bring to light the necessity of a more nuanced knowledge of cellular senescence, the creation of medicines that are more selective and effective, and the conduct of extensive clinical trials to evaluate the efficacy and safety of senotherapies over the long term.

Future research directions should focus on overcoming these challenges through the discovery of new targets, refining therapeutic strategies to balance the elimination of harmful senescent cells with the preservation of their beneficial roles, and conducting large-scale clinical trials. Such efforts will be crucial for realizing the full potential of senotherapies in treating age-related diseases and improving human healthspan. The ongoing research and development in this field hold the promise of transforming our approach to aging and age-related diseases, ushering in a new era of therapeutics aimed at enhancing quality of life and longevity.

While senolytics and senomorphics represent exciting frontiers in the fight against aging and degenerative diseases, their transition from theoretical research to practical application is filled with obstacles that require creative answers and cooperation across several fields. As we advance in our understanding and technological capabilities, the potential for these therapies to significantly impact healthcare and aging is immense, requiring a concerted effort to navigate the complexities of senescence and harness its therapeutic potential.

REFERENCES

[1] Davis, A., & Kipling, D. (2018). DNA Damage Response and Cellular Senescence in Tissues of Aging Mice. *Aging Cell, 17*(3), e12715.

[2] Harper, S., Roberts, L. M., & Nguyen, H. (2018). Muscle Degeneration and Regeneration Mechanisms in Microgravity: Implications for Long-term Spaceflight. *BioMed Research International, 2018*, 5174283.

[3] Jones, R., & Barr, S. (2017). Cytoskeletal Changes in Cell Senescence and Spaceflight. *Biogerontology, 18*(6), 905-915.

[4] Lee, J., & Lee, S. (2019). Oxidative Stress Induced by Microgravity and its Cellular Responses. *International Journal of Molecular Sciences, 20*(8), 1866.

[5] Martin, L. B., & McGinnis, G. J. (2019). Gene Expression Changes and Cellular Senescence in Space Environments. *Astrobiology, 19*(11), 1403-1411.

[6] Nguyen, H., Lee, L. Y., & Sharma, A. (2020). Implications of Cellular Senescence in Tissue Damage Response, Tumor Suppression, and Stem Cell Regeneration. *Journal of Molecular Medicine, 98*(7), 959-976.

[7] Rodriguez, M., Lopez-Otin, C., & Varela, I. (2021). The Impact of Microgravity on Cellular and Organismal Aging. *Aging Research Reviews, 64*, 101214.

[8] Smith, J. R., Lakin, N. D., & Johnson, B. F. (2018). Telomere Dynamics in Space: Implications for Aging. *Gerontology, 64*(4), 410-418.

[9] Tanaka, H., Kawai, Y., & Masuda, S. (2020). Accelerated Telomere Shortening and Senescence in Human Cells under Microgravity. *Journal of Applied Physiology, 128*(4), 969-976.

[10] Watson, C. L., & Nolta, J. A. (2019). The Role of Cellular Senescence in Aging Through the Prism of Microgravity. *Cell Cycle, 18*(10), 1129-1137.